Particle Sciences, a CDMO for drug eluting devices, has added to its investment in development and manufacturing capabilities with the addition of a new 18mm extruder. According to Karl Mueller, Particle Sciences’ Associate Director Clinical Production, “The company has been expanding at a nice pace adding clean room square footage, equipment and staff across the board, all aimed at better serving our clients.
“The company now has over 6000ft2 of operating cleanroom and cGMP warehouse space including ISO5 (sterile) and two dedicated highly potent suites. The device group has been extremely productive bringing several products into the clinic in the last few months with more in pipeline. Particle Sciences is unique in its ability to bring such products from concept to the clinic, especially when they involve highly potent compounds which most implants do.”
Mark Mitchnick, Particle Sciences’ CEO added, “The staff continues to skillfully execute on the goal of being the premiere CDMO in the area of complex formulations which of course includes drug eluting devices. In response, the marketplace is validating the effort and our business is growing at a record pace.”
